Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1/2
35
about 2.8 years
18+
1 site in NY
What this study is about
Researchers are testing a treatment with pegcetacoplan and mFOLFIRINOX to see if it can be safe, tolerable, and effective in treating metastatic pancreatic cancer. The trial also looks at whether pegcetacoplan helps prevent blood clots and reduce the risk of serious complications from those clots.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Fluorouracil
- 2.Take Irinotecan
- 3.Take Leucovorin Calcium
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
fluorouracil (Antimetabolite; mimics uracil to disrupt DNA/RNA in cancer cells), irinotecan, calcium folinate, oxaliplatin, pegcetacoplan
oral (Oral Capsule), injection (Injection)
Primary: Incidence of treatment-related adverse events (AE) (Phase I), Progression-free survival (Phase II)
Secondary: Disease control rate (DCR), Overall response rate (ORR), Overall survival
biopsy, diagnostic, imaging
Oncology